Catch up on all updates and advancements shared at this year's Revolutionizing Atopic Dermatitis (RAD) Conference in Nashville, Tennessee.

Jamie Restivo, MPAS, PA-C, shares her key takeaways from the second day of the recent Fall Clinical PA/NP Conference in Orlando, Florida.

At SCALE 2025, Christina Feser, DO, FAAD, FAOCD, spotlighted the rapidly expanding pipeline of diverse therapies for patients with HS.

Discover insights from Peter Lio, MD, on precision medicine in pediatric atopic dermatitis and the promising role of ruxolitinib at the RAD 2025 Conference.

At RAD 2025, Maureen Offiah, MD, reflected on the sessions she felt were the most impactful as an attendee.

At RAD 2025, Matthew Zirwas, MD, outlined 2 upcoming shifts in dermatology: the emergence of povorcitinib for hidradenitis suppurativa and the anticipated generic availability of tofacitinib.

Maureen Offiah, MD, reflected on the key takeaways as an attendee at the 2025 Revolutionizing Atopic Dermatitis (RAD) Conference in Nashville, Tennessee.

Jamie Restivo, MPAS, PA-C, shares her key takeaways from the first day of the recent Fall Clinical PA/NP Conference in Orlando, Florida.

At RAD 2025, Matthew Zirwas, MD, explored the distinct clinical profiles of IL-31 and IL-13 inhibitors, highlighting nemolizumab’s potential superiority for itch relief.

At RAD 2025, the DISCOVER trial showed that dupilumab monotherapy significantly improved moderate to severe AD symptoms in this patient population.

At the 2025 EULAR meeting, UCB presented new 3-year data on bimekizumab for PsA.

At the Fall Clinical PA/NP 2025 Conference, attendees caught up on the ins and outs of CHE.

At RAD 2025, Christopher Bunick, MD, PhD, presented data on amlitelimab and rocatinlimab, highlighting their potential to suppress cytokine signaling and more.

Galderma unveils promising long-term data on nemolizumab for atopic dermatitis, showcasing significant skin improvement and quality of life enhancements.

Discover innovative insights from the JADE REAL study on flexible dosing of abrocitinib for managing moderate to severe atopic dermatitis.

Recent research presented at the 2025 RAD Meeting explored the use of ruxolitinib cream in combination with systemic therapy.

Raj Chovatiya, MD, PhD, MSCI, discussed his approach to personalizing treatment dosing plans with adult patients based on skin clearance and therapeutic type at RAD 2025.

At RAD 2025, Brad Glick, DO, MPH, reviewed the clinical signs of topical steroid withdrawal, the need for detailed patient histories to distinguish it from severe AD flares, and the role of targeted non-steroidal and systemic therapies.

At RAD 2025, Vimal H. Prajapati, MD, shared phase 4 data from the CAN UpTIMISE study that shows switching to upadacitinib after inadequate response with dupilumab achieved rapid and significant improvements in skin clearance, itch, and QOL.

At the 2025 Revolutionizing Atopic Dermatitis Conference, JiaDe “Jeff” Yu, MD, MS, discussed the multifactorial nature of chronic hand eczema, highlighting its distinction from atopic dermatitis.